263P - Clinical sequencing system for pancreatic cancer as a laboratory examination

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Pancreatic Cancer
Translational Research
Presenter Hideyuki Hayashi
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors H. Hayashi1, S. Tanishima2, R. Mori2, Y. Kawamoto3, I. Kinoshita4, Y. Komatsu3, H. Dosaka-Akita4, H. Nishihara1
  • 1Division Of Clinical Cancer Genomics, Hokkaido University Hospital, 060-8648 - Sapporo/JP
  • 2Department Of Biomedical Informatics Development, Mistubishi Space Software Co., Ltd, 105-6132 - Tokyo/JP
  • 3Department Of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, 060-8638 - Sapporo/JP
  • 4Department Of Medical Oncology, Hokkaido University Hospital, 060-8648 - Sapporo/JP



We have launched in-house clinical sequencing system called “CLHURC” and started clinical sequencing for cancer patients as a medical service in clinical practice from April 2016. Since then we have conducted comprehensive genetic testing against several cancer-related genes for patients with all type of cancer including pancreatic cancer.


In our system, genomic DNA was extracted from both pancreatic cancer tissue and normal blood serum obtained from the patients along with in-house clinical biobank system having high-quality tissue control and processing. Therefore we can utilize good quality genomic DNA for sequencing even if the tissue sample was obtained in tiny amount with endoscopic ultrasound-guided fine-needle aspiration biopsy. Gene alterations were identified using in-house automated gene analysis system. Attaching a meaning to the gene alterations and recommended treatment based on genomic information were discussed at the team-conference consisting of medical oncologists, pathologists, clinical laboratory technologists, bioinformaticians and clinical geneticists. We consequently make out a report for individual patient with genomic information including actionable gene alteration, druggable gene alteration, variant of uncertain significance, microsatellite instability and mutation rate. The period from the initial visit to the reporting the results to the patients was aimed at achieving within 14 days.


We had performed a clinical sequencing using CLHURC system for 43 cancer patients in four months (from April 1 to July 31 2016). Of them, the number of pancreas cancer patients was seven. Actionable gene mutation was detected in all of them (7/7, 100%), however potentially druggable gene mutation was detected only in two of them (2/7, 30%). Incidental germline gene mutation was detected in one of them (1/7, 14%).


Gene profile based treatment strategy and subsequent attempt to realize precision medicine for pancreatic cancer are steadily ongoing in an effort to achieve improved treatment outcome of the disease.

Clinical trial indentification

Legal entity responsible for the study

Hideyuki Hayashi


Hokkaido University Hospital


All authors have declared no conflicts of interest.